Skip to main
  1. Stocks
  2. Omeros
  3. Forecast
OMER

Omeros (OMER) Stock Forecast & Price Target

Omeros (OMER) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Omeros is attractive fundamentally because Yartemlea has shown a strong U.S. launch, with 2Q sales of $28.5M, 74 unique ordering accounts, and about 75% of orders coming from adults, suggesting broadening adoption rather than a narrow early pull-forward. The company’s outlook is further supported by reimbursement tailwinds from the permanent J-code and NTAP, which should reduce friction and improve hospital economics, while physician feedback points to roughly 30% to 35%+ market penetration and about $400M in peak sales even with almost no Europe contribution. Although the negative CHMP opinion is a near-term overhang, the market appears to assign limited European value already, so a reversal or partnership would be incremental upside on top of a still-compelling U.S. growth story.

Bears say

Omeros is highly exposed to binary clinical and regulatory outcomes, with narsoplimab representing the near-term value driver and the company already facing a negative CHMP opinion in Europe for TA-TMA. The setback increases uncertainty around approval and commercialization, while competition from larger, better-resourced biotech peers further weakens its ability to convert pipeline progress into durable profitability. The negative outlook is reinforced by rising go-forward R&D spend, a lower exit multiple, and a risk-adjusted DCF that now uses a 13.1% WACC, reflecting material regulatory, clinical, commercialization, and development risk.

Omeros (OMER) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.

Omeros (OMER) Analyst Forecast & Price Prediction

Get the latest Omeros (OMER) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Omeros (OMER)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Omeros (OMER) Forecast

Analysts have given Omeros (OMER) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Omeros (OMER) has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Omeros (OMER)


Omeros (OMER) Analyst Forecast & Price Prediction

Get the latest Omeros (OMER) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Omeros (OMER)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover OMER stock data and trends